Author: admin

  • Bastoni: ‘Gattuso gave Italy some slaps, we needed a wake-up call’

    Bastoni: ‘Gattuso gave Italy some slaps, we needed a wake-up call’

    Alessandro Bastoni admits Gennaro Gattuso gave Italy ‘determination, grit, and a fair few slaps, as perhaps we needed a wake-up call’ ahead of their 5-0 win over Estonia.

    The Inter defender got a rare goal in the Azzurri jersey, popping up to meet the Giacomo Raspadori cross in the final minute on a short corner.

    Advertisement

    This completed the 5-0 rout in Bergamo, after a Mateo Retegui brace, plus goals from Moise Kean and Raspadori.

    Bastoni sees fresh start for Italy under Gattuso

    BERGAMO, ITALY – SEPTEMBER 05: Alessandro Bastoni of Italy celebrates with teammates after scoring his team’s fifth goal during the FIFA World Cup 2026 qualifier match between Italy and Estonia at Stadio di Bergamo on September 05, 2025 in Bergamo, Italy. (Photo by Mattia Ozbot/Getty Images)

    “I think these five goals come from our hunger and determination, quite aside from the technical quality,” Bastoni told Sky Sport Italia.

    “The fact is, we’ve always had quality, but we have to bring it out and take responsibility on the field. It was a good test, aside from the level of the opponents, as we were concentrated, careful on preventative marking, determined in attack. We did well.”

    Advertisement

    It was the debut for new Italy coach Gattuso, who had taken over from sacked Luciano Spalletti in June after a dismal start to the 2026 World Cup qualifying campaign.

    BERGAMO, ITALY – SEPTEMBER 05: Coach Gennaro Gattuso of Italy gesture during the FIFA World Cup 2026 qualifier match between Italy and Estonia at Stadio di Bergamo on September 05, 2025 in Bergamo, Italy. (Photo by Mattia Ozbot/Getty Images)

    “I never had Gattuso as a teammate, but I can imagine what that was like!” laughed Bastoni.

    “He gives us so much determination and grit, a fair few slaps too, which perhaps we needed to have a wake-up call. I think we needed that lately.”

    Advertisement

    Check the Football Italia Player Ratings for Italy 5-0 Estonia

    BERGAMO, ITALY – SEPTEMBER 05: Players of Italy during the National Anthem during the FIFA World Cup 2026 qualifier match between Italy and Estonia at Stadio di Bergamo on September 05, 2025 in Bergamo, Italy. (Photo by Mattia Ozbot/Getty Images)

    Does this feel like the start of a new and stronger era for the Nazionale?

    “It’s too early to tell. We’ve had other games under different coaches where we thought that we were on the right path, only for the problems to re-emerge again. We’ll give it our all and hope to carry on like this.”

    Gattuso radically changed from Spalletti with a 4-2-3-1 formation, or a 4-2-4 depending on how you look at it, with Retegui, Kean, Mattia Zaccagni and Matteo Politano all together.

    Advertisement

    “I like it, as it’s three building out from the back, but when one goes up, we have to cover him. It’s early days, but we are happy with the signs from this game,” concluded Bastoni.

    They are back in action on Monday evening against Israel, who are second in Group I and won 4-0 away to Moldova tonight.

    Continue Reading

  • JAKi for Atopic Dermatitis Comparable to IL-4, IL-13 Inhibitors in Cancer, Heart Disease Risk

    JAKi for Atopic Dermatitis Comparable to IL-4, IL-13 Inhibitors in Cancer, Heart Disease Risk

    Sizheng Steven Zhao, MBChB, PhD

    Credit: University of Manchester

    Individuals with atopic dermatitis who initiate systemic Janus kinase (JAK)-inhibitors are not at greater risk of developing cardiovascular disease or cancer compared to those initiating interleukin (IL)-4 or IL-13 inhibitors, recent data suggest.1

    These data comparing rates of risk between these 2 patient groups were the result of a recent study authored by investigators such as Sizheng Steven Zhao, MBChB, PhD, a clinical senior lecturer and consultant rheumatologist at the University of Manchester’s Centre for Musculoskeletal Research.

    Zhao and colleagues highlighted the well-known efficacy of JAK inhibitors (JAKi) for patients living with atopic dermatitis. They added, however, that cardiovascular and cancer risk concerns have remained persistent, given a prior study pointing to increased risk among patients with rheumatoid arthritis (RA).2

    “While the RA and [atopic dermatitis] populations likely differ, [atopic dermatitis] is independently associated with an increased risk of cardiovascular disease and cancer compared with the general population,” Zhao and coauthors wrote.1,3 “We aimed to compare the risk of cardiovascular disease and cancer between individuals starting systemic JAKi versus IL-4/-13 inhibitors (IL-4/-13i).”

    The investigative team used electronic health record data from healthcare systems primarily located in North America to conduct this cohort study. Those deemed eligible to be participants were required to be adults aged ≥18 years and to have an ICD-10 diagnosis code for atopic dermatitis. They also had to have initiated treatment with either a JAKi such as upadacitinib, tofacitinib, or abrocitinib or to have initiated an IL-4/IL-13 inhibitor such as lebrikizumab, dupilumab, or tralokinumab.

    The main outcomes Zhao et al assessed were the occurrence of coronary artery disease or stroke, and the incidence of any form of cancer among patients. In their evaluation of secondary endpoints, outcomes included coronary artery disease alone, skin cancer, stroke alone, and 2 control outcomes—herpes zoster and conjunctivitis.

    The investigative team applied 1:1 propensity score (PS)-matched Cox proportional hazards models to draw comparisons of time-to-event outcomes between treatment cohorts in their analysis. Zhao and colleagues included matching variables such as participants’ sex, age at initiation of treatment, sex, and ethnicity. The team assessed other covariates within the 12 months before initiation of these medications, including C-reactive protein (CRP) levels, ischemic heart disease, body mass index (BMI), cerebrovascular disease, cardiovascular risk factors, proxies for atopic dermatitis severity, and cancer history.

    Zhao and coauthors’ follow-up period continued until the last available record or the conclusion of the study period, whichever occurred first. Individuals involved in the analysis who shifted to 1 drug from another treatment class during follow-up were not included. The analyses were repeated for 1-, 3-, and 5-year follow-up intervals, with investigators hoping to address potential differences in exposure duration. They also conducted sensitivity analyses, excluding participants who reported a prior history of the outcome of interest. They would also remove events that took place within the first month of follow-up to limit reverse causation.

    In total, there were 1978 subjects who began using a JAK inhibitor and were successfully matched to 1978 IL-4/IL-13 inhibitor initiators. Mean follow-up duration was shown by the investigative team to have been slightly longer for IL-4/IL-13 inhibitor users (e.g., 291 days versus 264 days at the 1-year timepoint). All covariates at the point of baseline were well-balanced across the different cohorts of patients. Overall, the team found no statistically significant differences observed between drug classes in risk of any cancers (HR 0.81; 95% CI 0.60–1.08), cardiovascular events (HR 1.41; 95% CI 0.78–2.56), or skin cancers specifically (HR 1.07; 95% CI 0.61–1.89).1

    Zhao et al’s findings in this study were consistent across 1-, 3-, and 5-year follow-up periods and across their sensitivity analyses. However, JAKi therapy was linked with a decreased risk of conjunctivitis and an increased risk of herpes zoster. Nevertheless, this large real-world study’s findings indicate that, among adult patients with atopic dermatitis, JAK inhibitors do not appear to raise their risk of developing cardiovascular disease or cancer when compared with IL-4/IL-13 inhibitors.1

    Such conclusions may allow for reassurance among patients and clinicians, and the findings were consistent with both atopic dermatitis clinical trial data and previous observational research in RA. The investigators did acknowledge, however, the relatively limited number of outcome events and the consequent constraint on the data’s statistical power, highlighting the value of continued monitoring and replication in future studies.

    “The main limitation is the inability to accurately ascertain the drug cessation date using administrative data and the differences in follow-up time between exposure groups,” Zhao et al concluded.1 “However, results were similar across different durations of follow-up. As with all observational studies, residual confounding may bias our results. Nonetheless, reassurance comes from using IL-4/-13i as an active comparator and from the use of control outcomes.”

    References

    1. Zhao SS, Hernandez G, Alam U. Risk of Cardiovascular Disease and Cancer in Patients Initiating JAK Versus IL-4/-13 Inhibitors for Atopic Dermatitis. Int J Dermatol. 2025 Apr 28. doi: 10.1111/ijd.17815. Epub ahead of print. PMID: 40293104. Accessed September 5, 2025.
    2. Ytterberg SR, Bhatt DL, Mikuls TR, Connell CA, et al; ORAL Surveillance Investigators. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927. PMID: 35081280. Accessed September 5, 2025.
    3. Silverwood RJ, Forbes HJ, Langan SM, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ. 2018 May 23;361:k1786. doi: 10.1136/bmj.k1786. PMID: 29792314; PMCID: PMC6190010. Accessed September 5, 2025.

    Continue Reading

  • Prince William & Kate Middleton Speak Out About the Devastating Loss of a ‘Much Missed’ Family Member

    Prince William & Kate Middleton Speak Out About the Devastating Loss of a ‘Much Missed’ Family Member

    Prince William and Kate Middleton are sharing their grief after the loss of a member of the British Royal Family.

    The Duke and Duchess of Cambridge shared a statement on their social media pages after the death of Katharine, the Duchess of Kent on September 5.

    More from SheKnows

    “Our thoughts today are with The Duke of Kent and his family, particularly George, Helen and Nicholas,” they wrote. “The Duchess worked tirelessly to help others and supported many causes, including through her love of music. She will be a much missed member of the family.”

    Their note was signed “W & C,” their first initials.

    The Duchess of Kent, who was known for her kindness and humanity in the Royal Family, was 92 when she died. She became a Royal upon marrying Queen Elizabeth’s cousin Prince Edward, the Duke of Kent, in 1961. The couple welcomed three children together during their marriage: George, Earl of St. Andrews, Lady Helen Windsor and Lord Nicholas Windsor.

    Katharine was also open about experiencing a miscarriage and giving birth to a stillborn son, becoming an advocate for those who had gone through the same thing.

    Katharine took a more low-key approach to life as a royal and served as a music teacher in a school for over a decade in the 90s and 2000s instead of keeping up with public duties. In 2004, she founded the charity Future Talent, an organization that provides access to children who aren’t able to afford music lessons.

    Her death was announced in a September 5 statement. “It is with deep sorrow that Buckingham Palace announces the death of Her Royal Highness The Duchess of Kent,” the statement read.

    “Her Royal Highness passed away peacefully last night at Kensington Palace, surrounded by her family,” the statement continued. “The King and Queen and all Members of The Royal Family join The Duke of Kent, his children and grandchildren in mourning their loss and remembering fondly The Duchess’s life-long devotion to all the organizations with which she was associated, her passion for music and her empathy for young people.”

    Before you go, click here to see the 100 best photos of the royal family from the past 20 years.

    Best of SheKnows

    Sign up for SheKnows’ Newsletter. For the latest news, follow us on Facebook, Twitter, and Instagram.

    Continue Reading

  • Global Semiconductor Sales Increase 20.6% Year-to-Year in July

    Global Semiconductor Sales Increase 20.6% Year-to-Year in July

    Friday, Sep 05, 2025, 5:00pm

    by Semiconductor Industry Association

    Worldwide chip sales increase 3.6% month-to-month

    WASHINGTON—September 5, 2025—The Semiconductor Industry Association (SIA) today announced global semiconductor sales were $62.1 billion during the month of July 2025, an increase of 20.6% compared to the July 2024 total of $51.5 billion and 3.6% more than the June 2025 total of $59.9 billion. Monthly sales are compiled by the World Semiconductor Trade Statistics (WSTS) organization and represent a three-month moving average. SIA represents 99% of the U.S. semiconductor industry by revenue and nearly two-thirds of non-U.S. chip firms.

    “Global semiconductor sales remained robust in July, topping June’s results and far outpacing July of last year,” said John Neuffer, SIA president and CEO. “Growth continues to be driven by solid demand in the Asia Pacific region and the Americas.”

    Regionally, year-to-year in July sales were up in the Asia Pacific/All Other (35.6%), Americas (29.3%), China (10.4%), and Europe (5.7%), but decreased in Japan (-6.3%). Month-to-month sales in May increased in the Americas (8.6%) and Asia Pacific/All Other (4.9%), remained steady in Europe (0.0%), and declined in Japan (-0.2%) and China (-1.3%).

    For comprehensive monthly semiconductor sales data and detailed WSTS forecasts, consider purchasing the WSTS Subscription Package. For detailed historical information about the global semiconductor industry and market, consider ordering the SIA Databook.

    [July 2025 chart and graph]

    ###

    Media Contact
    Dylan Peterson
    Semiconductor Industry Association
    812-679-8952
    dpeterson@semiconductors.org 
    About SIA
    The Semiconductor Industry Association (SIA) is the voice of the semiconductor industry, one of America’s top export industries and a key driver of America’s economic strength, national security, and global competitiveness. SIA represents 99% of the U.S. semiconductor industry by revenue and nearly two-thirds of non-U.S. chip firms. Through this coalition, SIA seeks to strengthen leadership of semiconductor manufacturing, design, and research by working with Congress, the Administration, and key industry stakeholders around the world to encourage policies that fuel innovation, propel business, and drive international competition. Learn more at 
    www.semiconductors.org.
    About WSTS
    World Semiconductor Trade Statistics (WSTS) is an independent non-profit organization representing the vast majority of the world semiconductor industry. The mission of WSTS is to be the respected source of semiconductor market data and forecasts. Founded in 1986, WSTS is the singular source for monthly industry shipment statistics.

    Continue Reading

  • MSF welcomes addition of new diabetes medicines to WHO Essential Medicines List | Doctors Without Borders

    MSF welcomes addition of new diabetes medicines to WHO Essential Medicines List | Doctors Without Borders

    When a medicine is added to the WHO’s EML, it signals that it is vital for public health and should be made affordable and accessible, that countries should include it in national policies, and that corporations should register it in-country so more people can access it. Currently, rapid-acting insulins and GLP-1s are generally unaffordable and often unavailable in the places MSF operates.

    Rapid-acting insulin analogues and GLP-1s help manage blood sugar levels, reducing the likelihood of potential diabetes-related health complications and the need for additional care—something that can be difficult to access for people in low- and middle-income countries.

    Continue Reading

  • Marmoush nets penalty as Egypt beat Ethiopia – Manchester City FC

    1. Marmoush nets penalty as Egypt beat Ethiopia  Manchester City FC
    2. World Cup 2026 qualifiers – Egypt vs Ethiopia: date, kick-off time, broadcast channels and head-to-head history  ca.sports.yahoo.com
    3. Egypt vs Ethiopia LIVE Score Updates: Two penalties secure victory (2-0)  VAVEL.com
    4. Preview: Egypt vs Ethiopia – prediction, team news, lineups  Sports Mole
    5. Egypt vs Ethiopia Preview, prediction, lineups, betting tips & odds | 2026 FIFA World Cup Qualifiers  Khel Now

    Continue Reading

  • Autozi Internet Technology (Global) Ltd. Reports First Half Fiscal Year 2025 Financial Results

    BEIJING, Sept. 5, 2025 /PRNewswire/ — Autozi Internet Technology (Global) Ltd. (“Autozi” or the “Company”) (Nasdaq: AZI), one of the leading and fast-growing lifecycle automotive service providers in China, today announced its unaudited financial results for the six months ended March 31, 2025.

    First Half of Fiscal Year 2025 Financial Highlights

    • Total revenues increased 65.9% year-over-year to US$79.9 million, compared with US$48.1 million in the same period of fiscal year 2024, driven by strong growth in auto parts and accessories sales.
    • Gross profit improved to US$1.4 million, compared with US$0.1 million in the same period of fiscal year 2024, with gross margin rising to 1.7% from 0.2%.
    • Operating loss widened to US$8.1 million, compared with US$2.1 million in the same period of fiscal year 2024. The increased operating expenses in the first half of fiscal year 2025 included certain one-off and non-cash expenses, such as expenses related to financing activities and share-based compensations.
    • Net loss was US$5.3 million, an increase of 11.6% from a net loss of US$4.7 million in the same period of fiscal year 2024.

    Chairman’s Letter to Shareholders

    Dear Shareholders,

    The first half of fiscal year 2025 was a pivotal period for Autozi as we continued to reshape our business and strengthen the foundation for sustainable, long-term growth. Our strategy has been clear: concentrate resources on the auto parts and accessories business, a business where we see scale, resilience, and long-term value creation, while deliberately scaling down lower-margin business including new car sales and insurance.

    This disciplined focus has already delivered tangible results. Our revenues increased by nearly 66% year-over-year, driven almost entirely by the rapid expansion of our core auto parts and accessories business, which grew to represent 98.7% of total revenues in the first half of fiscal year 2025 compared with 48.5% in the prior-year period. This dramatic shift in business mix underscores the effectiveness of our strategic repositioning and highlights the growing importance of our auto parts and accessories platform.

    We also made meaningful progress in improving our profitability. Gross profit increased significantly from the prior year, and gross margin expanded as the revenue contribution from the higher-margin auto parts and accessories business increased. While operating expenses were higher, a substantial portion of the increase stemmed from one-time financing costs and non-cash share-based compensation. Excluding these items, our underlying loss narrowed considerably, reflecting stronger operational discipline and a higher-quality margin profile.

    These results have given us the confidence to move forward decisively with our long-term strategic vision, which rests on two major directions. The first is electrification. As electric vehicle sales in China have already surpassed those of fuel-powered cars, we see enormous potential in aligning Autozi with this structural shift by developing capabilities in EV core components. The second is servicization. We are building a next-generation automotive supply chain service platform anchored by three pillars:

    • Capitalization: leveraging our status as a public company to partner with and support high-quality enterprises across the automotive value chain;
    • Digitalization: applying technology to enhance supply chain efficiency, visibility, and scalability for our partners and customers;
    • Globalization: expanding beyond China to help leading Chinese brands compete on the global stage, while broadening Autozi’s revenue base and exposure to international markets.

    Together, these two strategic directions provide a powerful roadmap for Autozi’s evolution. They will enable us to move into higher-margin, innovation-driven businesses while developing recurring service revenues, creating a more resilient and scalable business model that we believe will drive lasting shareholder value.

    We recognize that the road ahead will include challenges. Like many growth companies, we continue to face near-term pressures on profitability and liquidity. However, we are addressing these challenges with urgency and discipline. By focusing on our core strengths, improving efficiency, and executing on well-defined strategic initiatives, I am confident that Autozi is well-positioned to navigate short-term volatility while advancing toward long-term value creation.

    On behalf of the Board of Directors and the management team, I extend my deepest gratitude to our shareholders, employees, and partners for their trust and support. Your vote of confidence motivates us to push forward with clarity and conviction. Together, we are building a stronger Autozi, one that will play a leading role in the innovation, globalization, and electrification of the automotive industry.

    Dr. Houqi Zhang
    Founder, Chairman, and Chief Executive Officer of Autozi

    First Half of Fiscal Year 2025 Financial Results

    Revenues

    Revenues were US$79.9 million for the six months ended March 31, 2025, an increase of 65.9% or US$31.7 million compared with US$48.1 million in the same period of fiscal year 2024. The increase was primarily driven by a US$55.6 million increase in revenues from auto parts and accessories sales, which accounted for 98.7% of the Company’s total revenues in the first half of fiscal year 2025 compared to 48.5% in the same period of fiscal year 2024, reflecting the Company’s focus on this revenue stream. Higher procurement levels, particularly in lubricating oils, provided cost advantages and supported market expansion. This growth was partially offset by a combined US$23.9 million decline in revenues from new car sales and automotive insurance-related services, as the Company scaled down and temporarily suspended these lower-margin businesses in response to intensified market competition.

    Cost of Revenues

    Cost of revenues was US$78.5 million for the six months ended March 31, 2025, an increase of 63.5% or US$30.5 million from US$48.0 million in the same period of fiscal year 2024. The increase was mainly attributable to a US$54.3 million rise in costs related to auto parts and accessories sales as the Company further expanded this business, partially offset by a US$23.8 million reduction in costs associated with new car sales and automotive insurance-related services.

    Gross Profit

    Gross profit was US$1.4 million for the six months ended March 31, 2025, compared with US$0.1 million in the same period of fiscal year 2024. Gross margin improved to 1.7% from 0.2% a year ago. The year-over-year increase of US$1.2 million in gross profit was mainly attributable to a US$1.3 million improvement in auto parts and accessories margins, supported by larger procurement volumes and stronger bargaining power with upstream suppliers.

    Operating Expenses

    Operating expenses were US$9.5 million for the six months ended March 31, 2025, compared with US$2.2 million in the same period of fiscal year 2024, representing an increase of 336.9% or US$7.3 million. The increase was primarily due to a significantly higher revenue contribution from the auto parts and accessories business, which incurred higher selling and marketing expenses. In addition, the increase in operating expenses during the first half of fiscal 2025 also included certain one-off financing-related expenses and non-cash share-based compensation expenses..

    • General and administrative expenses increased by 422.4% to US$7.3 million, compared with US$1.4 million in the prior-year period. The increase was driven by (i) a US$3.2 million increase in consulting and professional service fees, of which approximately US$2.7 million related to financing activities in February 2025 and other financing activities; and (ii) a US$1.9 million increase in share-based compensation for management and administrative personnel.
    • Selling and marketing expenses rose by 332.7% to US$1.6 million, compared with US$0.4 million in the prior-year period. The increase was mainly attributable to US$0.7 million in share-based compensation for sales personnel and US$0.5 million in promotional and entertainment expenses as the Company expanded business development activities for its auto parts and accessories business.
    • Research and development expenses were US$0.6 million, up 51.0% from US$0.4 million in the same period of 2024. The increase was primarily due to an additional US$0.3 million in share-based compensation for to recruite and maintain top research and development talents.

    Other expenses or income, net

    Other income, net was US$2.8 million for the six months ended March 31, 2025, compared with other expenses, net of US$2.7 million in the same period of fiscal year 2024. The year-over-year variance was primarily driven by a gain of US$4.4 million recognized following the favorable final judgment in litigation with Hunan Tianhuan Economic Development Co., Ltd., which released the Company from obligations to pay certain penalties and legal fees related to the repurchase of mezzanine equity. This gain was partially offset by a US$0.6 million increase in interest expenses associated with new financing obtained in February 2025.

    Net loss

    As a result of the foregoing, the Company recorded a net loss of US$5.3 million for the six months ended March 31, 2025, compared with a net loss of US$4.7 million in the same period of 2024.

    Going Concern

    For the six months ended March 31, 2024 and 2025, the Company incurred net loss of US$4.7 million and US$5.3 million, respectively. As of March 31, 2025, the Company had an accumulated deficit of US$134.8 million and negative working capital of US$19.0 million. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date that the unaudited condensed consolidated financial statements are issued.

    The Company has funded the operations and capital needs primarily through the net proceeds received from capital contributions, bank borrowings and the initial public offering. To meet the cash requirements for the next 12 months from the issuance date of this interim financial information, the Company is undertaking a combination of the remediation plans:

    (a) The Company is seeking an extension of liabilities including bank loans, convertible bonds and corresponding interests to be paid until the funding shortage issue is resolved.

    (b) The Company is focusing on the improvement of operation efficiency, implementation of strict cost control and budget and enhancement internal controls to create synergy of the Company’s resources.

    (c) The Company plans to raise additional capital, including among others, obtaining debt and equity financing, to support our operating.

    The management plan cannot alleviate the substantial doubt of the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in achieving strategic plans, that the future capital raises will be sufficient to support its ongoing operations, or that any additional financing will be available in a timely manner or with acceptable terms, if at all. If the Company is unable to raise sufficient financing or events or circumstances occur such that the Company does not meet the strategic plans, or that it is unsuccessful in increasing profit and reducing operating losses, it would have a material adverse effect on the Company’s financial position, results of operations, cash flows, and ability to achieve intended business objectives.

    The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

    About Autozi Internet Technology (Global) Ltd.

    Autozi Internet Technology (Global) Ltd. is a leading, fast-growing provider of lifecycle automotive services in China. Founded in 2010, Autozi offers a comprehensive range of high-quality, affordable, and professional automotive products and services through both online and offline channels across the country. Leveraging its advanced online supply chain cloud platform and SaaS solutions, Autozi has built a dynamic ecosystem that connects key participants across the automotive industry. This interconnected network enables more efficient collaboration and streamlined processes throughout the entire supply chain, positioning Autozi as a key driver of innovation and growth in the automotive services sector.

    Forward-Looking Statements

    All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. These forward-looking statements speak only as of the date of this announcement, and the Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, as actual results may be impacted by a variety of factors, including without limitation, changes in macroeconomic conditions, industry dynamics, competitive landscape, regulatory requirements, the Company’s ability to successfully implement its growth strategies and effectively manage costs and operations, and unforeseen business challenges. The Company encourages investors to review other factors that may affect its future results in the Company’s registration statement, periodic reports, including its Annual Report on Form 20-F and Current Report on Form 6-K, and in its other filings with the SEC.

    Contact Information

    Autozi Internet Technology (Global) Ltd.
    Ms. Jiabing Song
    Email: [email protected] 

    AUTOZI INTERNET TECHNOLOGY (GLOBAL) LTD.


    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS


    (In U.S. dollars in thousands, except for share and per share data, or otherwise noted)








    As of

    September 30,



    As of

    March 31,




    2024



    2025


    ASSETS









    Current assets









    Cash and cash equivalents


    $

    1,972



    $

    349


    Restricted cash



    501





    Accounts receivable, net



    417




    239


    Advance to suppliers, net



    6,513




    6,904


    Inventories



    3,270




    1,387


    Prepayments, receivables and other assets, net



    8,120




    7,430


    Amounts due from related parties, net



    294




    61


    Total current assets



    21,087




    16,370











    Non-current assets









    Property, equipment and software, net



    427




    353


    Operating lease right-of-use assets



    343




    215


    Total non-current assets



    770




    568











    TOTAL ASSETS


    $

    21,857



    $

    16,938











    LIABILITIES AND SHAREHOLDERS’ DEFICIT









    Current liabilities









    Short-term borrowings


    $

    8,131



    $

    8,546


    Convertible bonds



    4,346




    4,203


    Accounts payable



    2,868




    2,092


    Deferred revenues



    6,545




    4,187


    Accrued expenses and other current liabilities



    17,189




    16,025


    Payable to redeemable non-controlling interests



    16,616





    Lease liabilities, current



    530




    160


    Amounts due to related parties



    767




    202


    Total current liabilities



    56,992




    35,415











    Non-current liabilities









    Lease liabilities, non-current



    42





    Total non-current liabilities



    42














    TOTAL LIABILITIES



    57,034




    35,415











    Commitments and contingencies

















    Shareholders’ deficit









    Class A ordinary shares (US$0.000001 par value; 480,000,000,000
    and 480,000,000,000 shares authorized as of September 30, 2024 and
    March 31, 2025, respectively; 70,386,100 shares and 82,586,100
    shares issued as of September 30, 2024 and March 31, 2025,
    respectively; 70,386,100 shares and 76,800,739 shares outstanding as
    of September 30, 2024 and March 31, 2025, respectively)







    Class B ordinary shares (US$0.000001 par value; 20,000,000,000 and
    20,000,000,000 shares authorized as of September 30, 2024 and
    March 31, 2025; 34,595,100 and 31,795,100 shares issued and
    outstanding as of September 30, 2024 and March 31, 2025,
    respectively)







    Additional paid-in capital



    84,824




    89,332


    Accumulated deficit



    (129,532)




    (134,771)


    Accumulated other comprehensive income



    10,967




    12,115


    Total AUTOZI shareholders’ deficit



    (33,741)




    (33,324)


    Non-controlling interests



    (1,436)




    14,847


    Total shareholders’ deficit



    (35,177)




    (18,477)











    TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT


    $

    21,857



    $

    16,938


    AUTOZI INTERNET TECHNOLOGY (GLOBAL) LTD.


    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
    COMPREHENSIVE LOSS


    (In U.S. dollars in thousands, except for share and per share data, or otherwise noted)






    For the six months ended March 31,




    2024



    2025




    (Unaudited)



    (Unaudited)


    Revenues


    $

    48,142



    $

    79,871


    Cost of revenues



    (48,031)




    (78,511)


    Gross profit



    111




    1,360











    Operating expenses









    Selling and marketing expenses



    (364)




    (1,575)


    General and administrative expenses



    (1,395)




    (7,288)


    Research and development expenses



    (412)




    (622)


    Total operating expenses



    (2,171)




    (9,485)











    Operating loss



    (2,060)




    (8,125)











    Other (expense) income









    Litigation related (expenses) income



    (1,438)




    4,381


    Interest expenses, net



    (1,333)




    (1,926)


    Other income, net



    101




    392


    Total other (expenses) income, net



    (2,670)




    2,847











    Loss before income tax expenses



    (4,730)




    (5,278)


    Income tax expenses







    Net loss


    $

    (4,730)



    $

    (5,278)


    Less: net (loss) income attributable to non-controlling interests



    (177)




    (39)


    Less: net loss attributable to mezzanine equity



    (69)





    Less: accretion of mezzanine equity to redemption value



    5,558





    Net loss attributable to the Company’s ordinary shareholders


    $

    (10,042)



    $

    (5,239)











    Net loss



    (4,730)




    (5,278)











    Foreign currency translation difference, net of tax of nil



    (1,522)




    1,470











    Total comprehensive loss


    $

    (6,252)



    $

    (3,808)


    Less: total comprehensive (loss) income attributable to non-controlling
    interests



    (185)




    283


    Comprehensive loss attributable to the Company


    $

    (6,067)



    $

    (4,091)











    Net loss per share of non-redeemable ordinary shares – Basic and
    diluted



    (0.10)




    (0.05)











    Weighted average shares of outstanding non-redeemable ordinary
    shares



    73,580,500




    106,059,912











    Net earnings per share of redeemable ordinary shares – Basic and
    diluted



    0.09














    Weighted average shares of outstanding redeemable ordinary shares



    28,900,700





    SOURCE Autozi Internet Technology (Global) Ltd.

    Continue Reading

  • Snapchat’s new AI Imagine Lens lets you become whoever you can describe

    Snapchat’s new AI Imagine Lens lets you become whoever you can describe


    • Snapchat’s new Imagine Lens uses AI to produce an image from any prompt
    • The feature blends generative AI with Snap’s real-time camera interface
    • The Lens is only available to Snapchat+ Platinum and Lens+ subscribers for now

    Snapchat has been offering AI-powered Lenses for pre-programmed filters for a while, but its newest feature lets you write out any prompt you want. The new Imagine Lens will alter your photos based on what you type, no matter how specific. You could take a selfie and ask it to “turn me into a four-panel comic where I become a jellyfish superhero,” and see that comic appear.

    Only available for Snapchat+ Platinum and Lens+ subscribers on iOS, Imagine Lens is the app’s first open-prompt AI image generator built into the Lens Carousel. Unlike Snapchat’s existing generative Lenses, which offer fun but fixed effects, this one actually listens to what you type. The resulting image can then be posted to your Story, saved to your camera roll, or shared with your friends. Unlike those existing Lenses, you won’t be able to make a video or see the overlay ahead of time, but Snap seems confident people will like the final result.

    Continue Reading

  • After 40 Years, Heart Doctors Say Beta Blockers May Do More Harm Than Good

    After 40 Years, Heart Doctors Say Beta Blockers May Do More Harm Than Good

    A groundbreaking international trial has found beta blockers don’t help most heart attack patients with preserved heart function, despite being standard care for decades. Even more concerning, women given the drug faced higher risks of death and complications. Credit: Stock

    For over 40 years, beta blockers have been prescribed to heart attack survivors as a standard treatment. But the massive REBOOT trial has revealed they provide no benefit for patients with preserved heart function — and may actually increase risks for women.

    Standard Treatment Questioned After 40 Years

    Beta blockers, commonly prescribed for heart conditions including heart attacks, have now been shown to offer no measurable benefit for patients who experience an uncomplicated myocardial infarction while maintaining normal heart function. Despite being recommended for this group for four decades, their effectiveness in such cases is now being called into question.

    The finding comes from the REBOOT Trial, a major study led by Valentin Fuster, MD, PhD, President of Mount Sinai Fuster Heart Hospital and General Director of Spain’s Centro Nacional de Investigaciones Cardiovasculares (CNIC). The results, which challenge one of cardiology’s longest-standing practices, were presented on August 30, during a “Hot Line” session at the European Society of Cardiology Congress in Madrid and published at the same time in The New England Journal of Medicine.

    Higher Risks for Women Exposed

    A companion substudy of REBOOT, released the same day in the European Heart Journal, revealed an important difference between men and women. Women who were treated with beta blockers after a heart attack faced a higher likelihood of dying, suffering another heart attack, or being hospitalized for heart failure when compared with women who did not receive the medication. This increased risk was not observed in men.

    “This trial will reshape all international clinical guidelines. It joins other previous landmark trials led by CNIC and Mount Sinai – such as SECURE with the polypill and DapaTAVI, with SLT2 inhibition associated to TAVI –that have already transformed some global approaches to cardiovascular disease,” says Dr. Fuster.

    Valentin Fuster
    Valentin Fuster, MD, PhD. “REBOOT Trial” shows beta blockers—drugs commonly prescribed for heart attacks—may offer no clinical benefit for these patients. Credit: Mount Sinai Health System

    The SECURE trial showed a polypill, a single pill that combines three medications – which contains aspirin, ramipril, and atorvastatin – reduces cardiovascular events by 33 percent in patients treated with this after a heart attack. The DapaTAVI trial showed that both dapagliflozin and the related medication empagliflozin – drugs used to treat diabetes – improve the prognosis of patients with aortic stenosis treated by transcatheter aortic valve implantation.

    Global Impact on Heart Attack Care

    “REBOOT will change clinical practice worldwide,” says Principal Investigator Borja Ibáñez, MD, CNIC’s Scientific Director, who presented the results. “Currently, more than 80 percent of patients with uncomplicated myocardial infarction are discharged on beta blockers. The REBOOT findings represent one of the most significant advances in heart attack treatment in decades.”

    Although generally considered safe, beta blockers can cause side effects such as fatigue, bradycardia (low heart rate), and sexual dysfunction. For more than 40 years, beta blockers have been prescribed as a standard treatment after a heart attack, but their benefit in the context of modern treatments was unproven. The REBOOT trial, is the largest clinical trial on this subject. The international study was coordinated by CNIC in collaboration with the Mario Negri Institute for Pharmacological Research in Milan.

    Largest Beta Blocker Study to Date

    Researchers enrolled 8,505 patients across 109 hospitals in Spain and Italy. Participants were randomly assigned to receive or not receive beta blockers after hospital discharge. All patients otherwise received the current standard of care and were followed for a median of nearly four years. The results showed no significant differences between the two groups in rates of death, recurrent heart attack, or hospitalization for heart failure.

    A REBOOT subgroup analysis found that women treated with beta blockers experienced more adverse events. Results show women treated with beta-blockers had a 2.7 percent higher absolute risk of mortality compared to those not treated with beta-blockers during the 3.7 years of follow-up of the study. The elevated risk when treated with beta-blockers was restricted to women with completely normal cardiac function after a heart attack (left ventricular ejection fraction of 50 percent or higher). Those with a mild deterioration in cardiac function did not have an excess risk of adverse outcomes when treated with beta-blockers.

    Why the Old Standard No Longer Fits

    “After a heart attack, patients are typically prescribed multiple medications, which can make adherence difficult,” explains Dr. Ibáñez. “Beta blockers were added to standard treatment early on because they significantly reduced mortality at the time. Their benefits were linked to reduced cardiac oxygen demand and arrhythmia prevention. But therapies have evolved. Today, occluded coronary arteries are reopened rapidly and systematically, drastically lowering the risk of serious complications such as arrhythmias. In this new context, where the extent of heart damage is smaller, the need for beta blockers is unclear. While we often test new drugs, it’s much less common to rigorously question the continued need for older treatments.”

    REBOOT Trial Motivation

    That was the motivation behind REBOOT.

    “The trial was designed to optimize heart attack care based on solid scientific evidence and without commercial interests. These results will help streamline treatment, reduce side effects, and improve quality of life for thousands of patients every year,” Dr. Ibanez adds.

    References:

    “Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction” by Borja Ibanez, Roberto Latini, Xavier Rossello, Alberto Dominguez-Rodriguez, Felipe Fernández-Vazquez, Valentina Pelizzoni, Pedro L. Sánchez, Manuel Anguita, José A. Barrabés, Sergio Raposeiras-Roubín, Stuart Pocock, Noemí Escalera, Lidia Staszewsky, Carlos Nicolás Pérez-García, Pablo Díez-Villanueva, Jose-Angel Pérez-Rivera, Oscar Prada-Delgado, Ruth Owen, Gonzalo Pizarro, Onofre Caldes, Sandra Gómez-Talavera, José Tuñón, Matteo Bianco, Jesus Zarauza, Alfredo Vetrano, Ana Campos, Susana Martínez-Huertas, Héctor Bueno, Miguel Puentes, Giulietta Grigis, Juan L. Bonilla-Palomas, Elvira Marco, José R. González-Juanatey, Roi Bangueses, Carlos González-Juanatey, Ana García-Álvarez, Juan Ruiz-García, Anna Carrasquer, Juan C. García-Rubira, Domingo Pascual-Figal, Carlos Tomás-Querol, J. Alberto San Román, Pasquale Baratta, Jaume Agüero, Roberto Martín-Reyes, Furio Colivicchi, Rosario Ortas-Nadal, Pablo Bazal, Alberto Cordero, Antonio Fernández-Ortiz, Pierangelo Basso, Eva González, Fabrizio Poletti, Giulia Bugani, Marzia Debiasio, Deborah Cosmi, Alessandro Navazio, Javier Bermejo, Giovanni Tortorella, Marco Marini, Javier Botas, José M. de la Torre-Hernández, Filippo Ottani and Valentín Fuster, 29 August 2025, New England Journal of Medicine.
    DOI: 10.1056/NEJMoa2504735

    “Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial” by Xavier Rossello, Alberto Dominguez-Rodriguez, Roberto Latini, Pedro L Sánchez, Sergio Raposeiras-Roubín, Manuel Anguita, José A Barrabés, Giulietta Grigis, Ruth Owen, Stuart Pocock, Sandra Gómez-Talavera, Ines García-Lunar, Noemí Escalera, Carlos Nicolás Pérez-García, Stefania Angela Di Fusco, Gonzalo Pizarro, María López Benito, Giulia Pongetti, Luis M Rincón-Díaz, Irene Buera, José Rozado, María Jesús García, Oscar Prada-Delgado, Deborah Cosmi, Valentín Fuster and Borja Ibanez, 30 August 2025, European Heart Journal.
    DOI: 10.1093/eurheartj/ehaf673

    Meeting: ESC Congress 2025

    REBOOT was conducted without pharmaceutical industry funding.

    Never miss a breakthrough: Join the SciTechDaily newsletter.

    Continue Reading

  • HIghlander Remake Casts Djimon Hounsou

    HIghlander Remake Casts Djimon Hounsou

     
    Two-time Academy Award nominee and frequent franchise player Djimon Hounsou is the latest bold-faced name to join the cast of Highlander, Amazon MGM’s remake of the 1980s cult classic.
     
    Henry Cavill is leading the cast that includes Russell Crowe and Marisa Abela as well as Dave Bautista and Karen Gillan, the latter two who notably appeared with Hounsou in Guardians of the Galaxy.
     
    The action fantasy, which hails from Amazon MGM’s United Artists banner, is being directed by Chad Stahelski and is slated for a theatrical release. Principal photography is due to begin at the end of September.
     
    Cavill is playing Connor MacLeod, a Medieval Scottish Highlander who discovers he is an immortal warrior. With the help of a swordsman named Ramirez, to be played by Crowe, the titular Highlander battles other immortals across the centuries, until, as the line in the original 1986 movie exclaimed, “there can be only one.”
     
    Hounsou will play an immortal warrior from Africa.
     
    Bautista is already on the roll call as The Kurgen, the movie’s top villain, while Gillan is MacLeod’s Scottish and very mortal wife. Abela is MacLeod’s modern romantic interest.
     
    Michael Finch wrote the script for the remake. Scott Stuber and Nick Nesbitt are producing via United Artists, alongside Neal H. Moritz, Stahelski’s 87Eleven Entertainment, Josh Davis of Davis Panzer Productions and Louise Rosner.

    Hounsou showed his dramatic chops with a breakthrough performance in Steven Spielberg’s Amistad, then earned Oscar nominations for In America and Blood Diamond.
     
    He played Korath the Pursuer in Guardians and other Marvel Cinematic Universe outings, appeared in the DC-based Shazam! franchise and in Zack Snyder’s sci-fi epic two-parter, Rebel Moon. He also appeared in two A Quiet Place movies.
     
    Among projects in the can are an untitled Sony Pictures thriller from writer-director Tommy Wirkola and produced by Adam McKay, and in Red Card opposite Halle Berry.
     
    Hounsou is repped by Buchwald, Range Media Partners, and Nelson Davis. 

    Continue Reading